Opioid and chemokine receptor crosstalk: A promising target for pain therapy?

Nature Reviews Neuroscience

Volumn 16, Issue 2, 2015, Pages 69-78

  Parsadaniantz, Stéphane Mélik ^a,b,c   Rivat, Cyril ^b,d   Rostène, William ^a,b,c   Réaux Le Goazigo, Annabelle ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; OPIATE RECEPTOR;

ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; CONCEPTUAL FRAMEWORK; DESENSITIZATION; DIMERIZATION; DRUG TARGETING; HUMAN; HYPERALGESIA; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MANAGED CARE; MOLECULAR INTERACTION; MORPHINE TOLERANCE; NERVE CELL; NEUROMODULATION; NONHUMAN; PAIN ASSESSMENT; PEPTIDERGIC NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REGULATORY MECHANISM; SENSORY NERVE CELL; SPINAL GANGLION; METABOLISM; PAIN; PHYSIOLOGY; SIGNAL TRANSDUCTION;

HUMANS; PAIN; PAIN MANAGEMENT; RECEPTOR CROSS-TALK; RECEPTORS, CHEMOKINE; RECEPTORS, OPIOID;

EID: 84926527691     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3858     Document Type: Article

References (109)

1. Abbadie, C. et al. Chemokines and pain mechanisms. Brain Res. Rev. 60, 125-134 (2009).
2. Grace, P. M., Hutchinson, M. R., Maier, S. F. & Watkins, L. R. Pathological pain and the neuroimmune interface. Nature Rev. Immunol. 14, 217-231 (2014).
3. Hutchinson, M. R. et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol. Rev. 63, 772-810 (2011).
4. White, F. A., Bhangoo, S. K. & Miller, R. J. Chemokines: integrators of pain and inflammation. Nature Rev. Drug Discov. 4, 834-844 (2005).
5. Rostene, W. et al. Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system. J. Neurochem. 118, 680-694 (2011).
6. Van Steenwinckel, J. et al. CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J. Neurosci. 31, 5865-5875 (2011).
7. Reaux-Le Goazigo, A., Van Steenwinckel, J., Rostene, W. & Melik Parsadaniantz, S. Current status of chemokines in the adult CNS. Prog. Neurobiol. 104, 67-92 (2013).
8. Rivat, C. et al. Src family kinases involved in CXCL12-induced loss of acute morphine analgesia. Brain Behav. Immun. 38, 38-52 (2014).
9. Szabo, I. et al. Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc. Natl. Acad. Sci. USA 99, 10276-10281 (2002).
10. Chen, X., Geller, E. B., Rogers, T. J. & Adler, M. W. Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats. Drug Alcohol Depend. 88, 36-41 (2007).
11. Zhao, P., Waxman, S. G. & Hains, B. C. Modulation of thalamic nociceptive processing after spinal cord injury through remote activation of thalamic microglia by cysteine cysteine chemokine ligand 21. J. Neurosci. 27, 8893-8902 (2007).
12. Latremoliere, A. & Woolf, C. J. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain 10, 895-926 (2009).
13. Johnston, I. N. et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J. Neurosci. 24, 7353-7365 (2004).
14. Oh, S. B. et al. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J. Neurosci. 21, 5027-5035 (2001).
15. Miller, R. J., Jung, H., Bhangoo, S. K. & White, F. A. Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol. 417-449 (2009).
16. Clark, A. K., Old, E. A. & Malcangio, M. Neuropathic pain and cytokines: current perspectives. J. Pain Res. 6, 803-814 (2013).
17. Roques, B. P., Fournié-Zaluski, M. C. & Wurm, M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nature Rev. Drug Discov. 11, 292-310 (2012).
18. Stein, C. & Machelska, H. Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol. Rev. 63, 860-881 (2011).
19. Happel, C., Steele, A. D., Finley, M. J., Kutzler, M. A. & Rogers, T. J. DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-β1. J. Leukoc. Biol. 83, 956-963 (2008).
20. Wetzel, M. A. et al. μ-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-γ-inducible protein-10 expression in human peripheral blood mononuclear cells. J. Immunol. 165, 6519-6524 (2000).
21. Benard, A. et al. δ opioid receptors mediate chemotaxis in bone marrow-derived dendritic cells. J. Neuroimmunol. 197, 21-28 (2008).
22. Grimm, M. C. et al. Opiates transdeactivate chemokine receptors: δ and μ opiate receptor-mediated heterologous desensitization. J. Exp. Med. 188, 317-325 (1998).
23. Pello, O. M. et al. Ligand stabilization of CXCR4/δ-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur. J. Immunol. 38, 537-549 (2008).
24. Labuz, D. et al. Immune cell-derived opioids protect against neuropathic pain in mice. J. Clin. Invest. 119, 278-286 (2009).
25. Boue, J., Blanpied, C., Brousset, P., Vergnolle, N. & Dietrich, G. Endogenous opioid-mediated analgesia is dependent on adaptive T cell response in mice. J. Immunol. 186, 5078-5084 (2011).
26. Rittner, H. L. et al. Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells. FASEB J. 20, 2627-2629 (2006).
27. Ye, D. et al. Activation of CXCL10/CXCR3 signaling attenuates morphine analgesia: involvement of Gi protein. J. Mol. Neurosci. 53, 571-579 (2014).
28. Grimm, M. C. et al. Opiate inhibition of chemokine-induced chemotaxis. Ann. NY Acad. Sci. 840, 9-20 (1998).
29. Rogers, T. J., Steele, A. D., Howard, O. M. & Oppenheim, J. J. Bidirectional heterologous desensitization of opioid and chemokine receptors. Ann. NY Acad. Sci. 917, 19-28 (2000).
30. Szabo, I. & Rogers, T. J. Crosstalk between chemokine and opioid receptors results in downmodulation of cell migration. Adv. Exp. Med. Biol. 493, 75-79 (2001).
31. Ranganathan, P., Chen, H., Adelman, M. K. & Schluter, S. F. Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity. J. Neuroimmunol. 217, 65-73 (2009).
32. Miyagi, T. et al. Morphine induces gene expression of CCR5 in human CEMx174 lymphocytes. J. Biol. Chem. 275, 31305-31310 (2000).
33. Steele, A. D., Henderson, E. E. & Rogers, T. J. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 309, 99-107 (2003).
34. Sengupta, R. et al. Morphine increases brain levels of ferritin heavy chain leading to inhibition of CXCR4-mediated survival signaling in neurons. J. Neurosci. 29, 2534-2544 (2009).
35. Patel, J. P. et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J. Neurovirol. 12, 492-500 (2006).
36. Ji, R. R. Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases. Curr. Drug Targets Inflamm. Allergy 3, 299-303 (2004).
37. Macey, T. A. et al. Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat. J. Pharmacol. Exp. Ther. 331, 412-418 (2009).
38. Zhang, N., Rogers, T. J., Caterina, M. & Oppenheim, J. J. Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize μ-opioid receptors on dorsal root ganglia neurons. J. Immunol. 173, 594-599 (2004).
39. Chen, X. et al. The effect of gp120 on morphine's antinociceptive and neurophysiological actions. Brain Behav. Immun. 25, 1434-1443 (2011).
40. Heinisch, S., Palma, J. & Kirby, L. G. Interactions between chemokine and μ-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey. Brain Behav. Immun. 25, 360-372 (2011).
41. Finley, M. J. et al. Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the κ-opioid receptor. J. Neuroimmunol. 197, 114-123 (2008).
42. Wilson, N. M., Jung, H., Ripsch, M. S., Miller, R. J. & White, F. A. CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav. Immun. 25, 565-573 (2011).
43. Reaux-Le Goazigo, A., Rivat, C., Kitabgi, P., Pohl, M. & Melik Parsadaniantz, S. Cellular and subcellular localization of CXCL12 and CXCR4 in rat nociceptive structures: physiological relevance. Eur. J. Neurosci. 36, 2619-2631 (2012).
44. Callewaere, C. et al. The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4. Proc. Natl Acad. Sci. USA 103, 8221-8226 (2006).
45. Kramp, B. K., Sarabi, A., Koenen, R. R. & Weber, C. Heterophilic chemokine receptor interactions in chemokine signaling and biology. Exp. Cell Res. 317, 655-663 (2011).
46. Burbassi, S., Sengupta, R. & Meucci, O. Alterations of CXCR4 function in mu-opioid receptor-deficient glia. Eur. J. Neurosci. 32, 1278-1288 (2010).
47. Suzuki, S., Chuang, L. F., Yau, P., Doi, R. H. & Chuang, R. Y. Interactions of opioid and chemokine receptors: oligomerization of μ, κ, and δ with CCR5 on immune cells. Exp. Cell Res. 280, 192-200 (2002).
48. Yuan, Y. et al. Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the μ opioid receptor and the chemokine receptor CCR5. Org. Biomol. Chem. 10, 2633-2646 (2012).
49. Parenty, G., Appelbe, S. & Milligan, G. CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem. J. 412, 245-256 (2008).
50. Ali, H., Richardson, R. M., Haribabu, B. & Snyderman, R. Chemoattractant receptor cross-desensitization. J. Biol. Chem. 274, 6027-6030 (1999).
51. Steele, A. D., Szabo, I., Bednar, F. & Rogers, T. J. Interactions between opioid and chemokine receptors: heterologous desensitization. Cytokine Growth Factor Rev. 13, 209-222 (2002).
52. Zhang, N., Hodge, D., Rogers, T. J. & Oppenheim, J. J. Ca2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J. Biol. Chem. 278, 12729-12736 (2003).
53. Song, C. et al. Protein kinase Cζ mediates microopioid receptor-induced cross-desensitization of chemokine receptor CCR5. J. Biol. Chem. 286, 20354-20365 (2011).
54. Cabioglu, N. et al. CXCL-12/stromal cell-derived factor-1α transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 65, 6493-6497 (2005).
55. Kramer, H. K. et al. Mutation of tyrosine 318 (Y318F) in the δ-opioid receptor attenuates tyrosine phosphorylation, agonist-dependent receptor internalization, and mitogen-activated protein kinase activation. Brain Res. Mol. Brain Res. 79, 55-66 (2000).
56. Kam, A. Y., Chan, A. S. & Wong, Y. H. κ-opioid receptor signals through Src and focal adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human monocytic THP-1 cells. J. Pharmacol. Exp. Ther. 310, 301-310 (2004).
57. Walwyn, W., Evans, C. J. & Hales, T. G. β-arrestin2 and c-Src regulate the constitutive activity and recycling of μ opioid receptors in dorsal root ganglion neurons. J. Neurosci. 27, 5092-5104 (2007).
58. Archer-Lahlou, E. et al. Src promotes delta opioid receptor (DOR) desensitization by interfering with receptor recycling. J. Cell. Mol. Med. 13, 147-163 (2009).
59. Zhang, L., Zhao, H., Qiu, Y., Loh, H. H. & Law, P. Y. Src phosphorylation of micro-receptor is responsible for the receptor switching from an inhibitory to a stimulatory signal. J. Biol. Chem. 284, 1990-2000 (2009).
60. Eijkelkamp, N. Losing touch with opioids: new insights into a chemokine signaling cascade controlling morphine analgesia. Brain Behav. Immun. 38, 36-37 (2014).
61. King, T., Ossipov, M. H., Vanderah, T. W., Porreca, F. & Lai, J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 14, 194-205 (2005).
62. Laulin, J. P. et al. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth. Analg. 94, 1263-1269 (2002).
63. Kissin, I., Brown, P. T., Robinson, C. A. & Bradley, E. L. Jr. Acute tolerance in morphine analgesia: continuous infusion and single injection in rats. Anesthesiology 74, 166-171 (1991).
64. Kissin, I., Lee, S. S., Arthur, G. R. & Bradley, E. L. Jr. Time course characteristics of acute tolerance development to continuously infused alfentanil in rats. Anesth. Analg. 83, 600-605 (1996).
65. Laulin, J. P., Celerier, E., Larcher, A., Le Moal, M. & Simonnet, G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience 89, 631-636 (1999).
66. Rivat, C. et al. Spinal NK-1 receptor-expressing neurons and descending pathways support fentanyl-induced pain hypersensitivity in a rat model of postoperative pain. Eur. J. Neurosci. 29, 727-737 (2009).
67. Celerier, E. et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 92, 465-472 (2000).
68. Lenz, H. et al. Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. Pain 152, 1289-1297 (2011).
69. Zhou, H. Y., Chen, S. R., Chen, H. & Pan, H. L. Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. J. Neurosci. 30, 4460-4466 (2010).
70. Angst, M. S., Koppert, W., Pahl, I., Clark, D. J. & Schmelz, M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 106, 49-57 (2003).
71. Laulin, J. P., Larcher, A., Celerier, E., Le Moal, M. & Simonnet, G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur. J. Neurosci. 10, 782-785 (1998).
72. Rivat, C. et al. Fentanyl enhancement of carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-aspartate receptor antagonist ketamine. Anesthesiology 96, 381-391 (2002).
73. Richebe, P., Rivat, C., Laulin, J. P., Maurette, P. & Simonnet, G. Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats. Anesthesiology 102, 421-428 (2005).
74. Campillo, A. et al. Increased spinal dynorphin levels and phospho-extracellular signal-regulated kinases 1 and 2 and c-Fos immunoreactivity after surgery under remifentanil anesthesia in mice. Mol. Pharmacol. 77, 185-194 (2010).
75. Angst, M. S. & Clark, J. D. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104, 570-587 (2006).
76. Li, X., Angst, M. S. & Clark, J. D. Opioid-induced hyperalgesia and incisional pain. Anesth. Analg. 93, 204-209 (2001).
77. Gu, X., Wu, X., Liu, Y., Cui, S. & Ma, Z. Tyrosine phosphorylation of the N-methyl-D-aspartate receptor 2B subunit in spinal cord contributes to remifentanil-induced postoperative hyperalgesia: the preventive effect of ketamine. Mol. Pain 5, 76 (2009).
78. Drdla, R., Gassner, M., Gingl, E. & Sandkuhler, J. Induction of synaptic long-term potentiation after opioid withdrawal. Science 325, 207-210 (2009).
79. Celerier, E., Laulin, J. P., Corcuff, J. B., Le Moal, M. & Simonnet, G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J. Neurosci. 21, 4074-4080 (2001).
80. Vanderah, T. W. et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J. Neurosci. 21, 279-286 (2001).
81. Raghavendra, V., Tanga, F. & DeLeo, J. A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306, 624-630 (2003).
82. Hutchinson, M. R. et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav. Immun. 22, 1248-1256 (2008).
83. Zhao, C. M. et al. Spinal MCP-1 contributes to the development of morphine antinociceptive tolerance in rats. Am. J. Med. Sci. 344, 473-479 (2012).
84. Sun, Y., Sahbaie, P., Liang, D., Li, W. & Clark, J. D. Opioids enhance CXCL1 expression and function after incision in mice. J. Pain 15, 856-866 (2014).
85. Mika, J., Osikowicz, M., Makuch, W. & Przewlocka, B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur. J. Pharmacol. 560, 142-149 (2007).
86. Raghavendra, V., Rutkowski, M. D. & DeLeo, J. A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. 22, 9980-9989 (2002).
87. Chen, M. L. et al. Role of P2X7 receptor-mediated IL-18/IL-18R signaling in morphine tolerance: multiple glial-neuronal dialogues in the rat spinal cord. J. Pain 13, 945-958 (2012).
88. Hutchinson, M. R. et al. Evidence that opioids may have Toll-like receptor 4 and MD-2 effects. Brain Behav. Immun. 24, 83-95 (2010).
89. Eidson, L. N. & Murphy, A. Z. Blockade of Toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine. J. Neurosci. 33, 15952-15963 (2013).
90. Loram, L. C. et al. Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy. Brain Behav. Immun. 26, 1256-1264 (2012).
91. Horvath, R. J., Romero-Sandoval, E. A. & De Leo, J. A. Inhibition of microglial P2X4 receptors attenuates morphine tolerance, Iba1, GFAP and μ opioid receptor protein expression while enhancing perivascular microglial ED2. Pain 150, 401-413 (2010).
92. Cui, Y. et al. A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav. Immun. 22, 114-123 (2008).
93. Krady, J. K. et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54, 1559-1565 (2005).
94. Kremlev, S. G., Roberts, R. L. & Palmer, C. Minocycline modulates chemokine receptors but not interleukin-10 mRNA expression in hypoxic-ischemic neonatal rat brain. J. Neurosci. Res. 85, 2450-2459 (2007).
95. Fukagawa, H., Koyama, T., Kakuyama, M. & Fukuda, K. Microglial activation involved in morphine tolerance is not mediated by Toll-like receptor 4. J. Anesth. 27, 93-97 (2013).
96. Rozenfeld, R. & Devi, L. A. Receptor heteromerization and drug discovery. Trends Pharmacol. Sci. 31, 124-130 (2010).
97. Rostene, W., Kitabgi, P. & Parsadaniantz, S. M. Chemokines: a new class of neuromodulator? Nature Rev. Neurosci. 8, 895-903 (2007).
98. Murphy, P. M. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 54, 227-229 (2002).
99. Adler, M. W., Geller, E. B., Chen, X. & Rogers, T. J. Viewing chemokines as a third major system of communication in the brain. AAPS J. 7, E865-E870 (2005).
100. Busch-Dienstfertig, M. & Stein, C. Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain - basic and therapeutic aspects. Brain Behav. Immun. 24, 683-694 (2010).
101. Schreiter, A. et al. Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue. FASEB J. 26, 5161-5171 (2012).
102. Boue, J. et al. Immune conditions associated with CD4+ T effector-induced opioid release and analgesia. Pain 153, 485-493 (2012).
103. Mehalick, M. L., Ingram, S. L., Aicher, S. A. & Morgan, M. M. Chronic inflammatory pain prevents tolerance to the antinociceptive effect of morphine microinjected into the ventrolateral periaqueductal gray of the rat. J. Pain 14, 1601-1610 (2013).
104. Hurley, R. W. & Hammond, D. L. The analgesic effects of supraspinal μ and δ opioid receptor agonists are potentiated during persistent inflammation. J. Neurosci. 20, 1249-1259 (2000).
105. Sykes, K. T. et al. Mechanisms responsible for the enhanced antinociceptive effects of micro-opioid receptor agonists in the rostral ventromedial medulla of male rats with persistent inflammatory pain. J. Pharmacol. Exp. Ther. 322, 813-821 (2007).
106. Hoot, M. R., Sim-Selley, L. J., Selley, D. E., Scoggins, K. L. & Dewey, W. L. Chronic neuropathic pain in mice reduces μ-opioid receptor-mediated G-protein activity in the thalamus. Brain Res. 1406, 1-7 (2011).
107. Dansereau, M. A. et al. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J. Neurochem. 106, 757-769 (2008).
108. Milligan, E. D. et al. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur. J. Neurosci. 20, 2294-2302 (2004).
109. Zhou, D., Chen, M. L., Zhang, Y. Q. & Zhao, Z. Q. Involvement of spinal microglial P2X7 receptor in generation of tolerance to morphine analgesia in rats. J. Neurosci. 30, 8042-8047 (2010).